Quicking Biotech Co., Ltd. has established itself as a trusted partner in the field of preclinical research, offering comprehensive animal testing services designed to meet the highest scientific standards. Our organization understands that reliable data derived from well-conducted studies forms the bedrock of successful product development in the pharmaceutical, veterinary, and cosmetic industries. With decades of combined experience in biotech research, we have refined our methodologies to ensure that every animal test we perform delivers actionable and reproducible results for our clients. The decision to outsource animal testing to a specialized provider like Quicking Biotech allows companies to focus on their core innovations while leveraging our state-of-the-art facilities and regulatory expertise. We take pride in our transparent approach, which includes detailed study protocols, regular progress updates, and comprehensive final reports that withstand rigorous regulatory scrutiny. Our team of board-certified toxicologists and veterinarians works closely with each client to design studies that address their specific research questions and compliance requirements.

The landscape of biomedical research has evolved significantly over the past decade, and Quicking Biotech has consistently adapted to emerging standards and technologies in the field of animal testing. Our commitment to excellence is reflected in our accreditation by major international regulatory bodies, ensuring that studies conducted at our facilities are accepted by authorities worldwide. We specialize in a wide range of study types, including acute and chronic toxicity assessments, dermal irritation studies, ocular safety evaluations, and efficacy trials for novel therapeutics. By integrating modern diagnostic tools with traditional testing frameworks, we provide our clients with a comprehensive understanding of their product's safety and efficacy profile. To learn more about our company philosophy and operational standards, we encourage you to visit ourAbout Us page, where we detail our history and vision for ethical research. Our facility in Shanghai is equipped with cutting-edge instrumentation and staffed by highly trained professionals dedicated to advancing scientific knowledge while respecting the welfare of all animals in our care.

Quality animal testing remains an indispensable component of the drug development pipeline, providing critical data that cannot be adequately replicated through in vitro methods or computational models alone. Before any new pharmaceutical compound or cosmetic ingredient can be approved for human use, regulators require a thorough understanding of its potential toxicological effects and pharmacokinetic properties across multiple biological systems. Well-designed animal studies help researchers identify adverse effects early in the development process, thereby reducing the risk of costly late-stage failures and protecting human volunteers in clinical trials from unnecessary harm. The data generated from these studies also informs dosing regimens, route of administration decisions, and potential drug-drug interaction assessments that are essential for safe therapeutic use. For industries such as animal testing cosmetics, rigorous preclinical evaluation ensures that products applied to human skin or eyes meet stringent safety criteria before they ever reach store shelves. Quicking Biotech's expertise in designing and executing these complex studies makes us a preferred partner for companies seeking reliable, regulator-ready safety data.

The specific methodologies employed in modern animal testing have grown increasingly sophisticated, allowing researchers to extract maximum information from each study while minimizing the number of animals required. Historically, tests such as the Draize test for eye and skin irritation were conducted with less emphasis on refinement and reduction, but today's protocols incorporate humane endpoints and advanced scoring systems that reduce animal discomfort while maintaining scientific validity. At Quicking Biotech, we continuously review and update our standard operating procedures to align with the latest guidelines from the Organisation for Economic Co-operation and Development (OECD) and the International Council for Harmonisation (ICH). Our commitment to quality extends beyond mere compliance; we actively invest in research that seeks to replace, reduce, and refine animal use across our operations. This dedication to continuous improvement ensures that our clients receive data that is not only scientifically robust but also ethically generated and globally acceptable. The integration of biomarkers, imaging technologies, and telemetry into our study designs further enhances the value of the information we deliver to our partners.

Quicking Biotech operates under a comprehensive ethical framework that prioritizes the welfare of all animals involved in our research programs while maintaining the scientific integrity required for valid, reproducible results. We adhere strictly to the principles of the 3Rs—Replacement, Reduction, and Refinement—which guide every aspect of our study design and execution from initial planning through final reporting. Our institutional animal care and use committee reviews all proposed protocols to ensure that they meet or exceed local and international welfare standards, and we maintain full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Specialized protocols for beagle testing, for example, incorporate environmental enrichment, social housing whenever possible, and positive reinforcement training to reduce stress and improve data quality. Our veterinary staff receives ongoing training in the latest anesthetic, analgesic, and euthanasia techniques to ensure that pain and distress are minimized at every stage of a study. Transparency is a cornerstone of our ethical approach, and we welcome client visits and regulatory inspections as opportunities to demonstrate our commitment to humane science.

The conversation around companies that test on animals has intensified in recent years, with increasing public scrutiny and regulatory pressure to adopt more humane practices across the industry. Quicking Biotech embraces this scrutiny as a catalyst for positive change and has proactively implemented policies that go beyond baseline compliance with animal welfare regulations. We have established formal relationships with external ethics advisors and animal welfare organizations to ensure that our practices reflect the latest thinking in humane research methodology. Our facilities are designed with animal comfort in mind, featuring climate-controlled housing, appropriate lighting cycles, and enrichment devices that allow for natural behaviors. Staff members are trained to recognize signs of distress or illness and to intervene promptly, with clear protocols for early euthanasia when welfare criteria are triggered. By choosing Quicking Biotech, our clients can confidently communicate to their stakeholders and consumers that their animal testing data was generated under the most humane conditions possible. Our detailed animal welfare reports and standard operating procedures are available for review, and we maintain an open-door policy for ethical audits conducted by third-party organizations.

The accuracy and reproducibility of animal testing data depend heavily on the sophistication of the equipment and techniques employed throughout the study lifecycle, from dose preparation to sample analysis. Quicking Biotech has invested significantly in state-of-the-art instrumentation, including high-performance liquid chromatography-mass spectrometry systems, automated hematology analyzers, and multiplex immunoassay platforms that enable comprehensive biomarker profiling from minimal sample volumes. Our histopathology laboratory is equipped with digital slide scanners and image analysis software that allows for objective, quantifiable assessment of tissue changes without the variability inherent in manual scoring. These technological investments translate directly into higher quality data, lower detection limits, and more informative study outcomes for our clients. We have also implemented a laboratory information management system that ensures full chain-of-custody documentation, electronic signatures, and audit trails that satisfy the most stringent good laboratory practice requirements. Our technical staff undergoes continuous training to remain proficient with emerging technologies and to adapt established protocols for improved sensitivity and specificity.

Beyond traditional analytical platforms, Quicking Biotech has pioneered the use of advanced in-life monitoring techniques that capture real-time physiological data from study animals without causing unnecessary disturbance. Implantable telemetry devices allow continuous recording of blood pressure, heart rate, body temperature, and electrocardiogram parameters, providing a rich dataset that reveals subtle effects missed by intermittent manual measurements. Non-invasive imaging modalities such as micro-computed tomography, magnetic resonance imaging, and positron emission tomography enable longitudinal assessment of disease progression and treatment response in the same animal over time, dramatically reducing the number of animals required to achieve statistical power. Our toxicology group has also refined the modern application of the Draize test, incorporating objective measurement tools such as fluorophotometry and confocal microscopy to replace subjective visual scoring with quantitative endpoints. These methodological advances not only improve data quality but also support our 3Rs commitments by extracting more information from each animal used. We maintain a dedicated technology scouting team that evaluates emerging innovations and assesses their potential applicability to our testing portfolio, ensuring that our clients benefit from the latest scientific developments.Products page provides additional detail on the diagnostic kits and testing solutions that complement our comprehensive animal testing services.

Our collaboration with a leading European pharmaceutical company illustrates the value that Quicking Biotech brings to complex animal testing programs. The client required a comprehensive 28-day repeated-dose toxicity study for a novel monoclonal antibody candidate targeting an autoimmune disorder, and they selected Quicking Biotech based on our specialized experience with biologic therapeutics and our AAALAC accreditation. We designed a study that incorporated toxicokinetic sampling, anti-drug antibody analysis, and extensive immunophenotyping, all coordinated through a single point of contact on our project management team. The study was completed on time and within budget, and the resulting data package was accepted without queries by both the European Medicines Agency and the U.S. Food and Drug Administration during subsequent regulatory submissions. The client has since returned for four additional studies, citing our responsive communication, data quality, and flexible scheduling as key factors in their decision to continue the partnership. This case exemplifies how a well-executed animal test can accelerate drug development timelines while satisfying the most demanding regulatory expectations.

In another successful partnership, a multinational cosmetics company approached Quicking Biotech to evaluate the ocular and dermal safety of a new line of plant-based skincare formulations. Given the growing consumer demand for alternatives to traditional animal testing cosmetics, the client needed rigorous safety data that would support product claims while meeting regulatory requirements in markets such as China where certain animal tests were still mandated. Our team developed a tailored testing strategy that incorporated modern refinement techniques, including the use of topical anesthetics and reduced exposure durations, to minimize any potential discomfort while still generating the required safety data. The study results confirmed the favorable safety profile of the formulations, and the client successfully launched their product line across 15 countries within 18 months of study completion. We have since expanded our collaboration to include stability testing, preservative efficacy testing, and in vitro alternative method validation studies. These case studies demonstrate Quicking Biotech's ability to adapt our animal testing capabilities to the unique needs of diverse industries, from pharmaceuticals to cosmetics to veterinary medicine. You can read more about our latest projects and company updates on ourNews page.

Selecting the right contract research organization for animal testing is a decision that carries significant implications for product development timelines, regulatory success, and corporate reputation. Quicking Biotech differentiates itself through an unwavering commitment to data quality, ethical standards, and client service that has made us a preferred partner for organizations ranging from emerging biotech startups to Fortune 500 pharmaceutical companies. Our scientific team brings together expertise in toxicology, pharmacology, pathology, and veterinary medicine, allowing us to manage studies of any complexity with confidence and precision. We offer flexible engagement models that can accommodate everything from a single acute toxicity study to multi-year chronic testing programs, with dedicated project managers who serve as a single point of accountability throughout the study lifecycle. Our quality assurance unit conducts regular internal audits and participates in external proficiency testing programs to ensure that our data consistently meets or exceeds industry standards. For companies that are evaluating companies that test on animals as potential partners, Quicking Biotech offers site tours, detailed capability presentations, and confidential preliminary consultations at no charge.

Our competitive advantages extend beyond scientific and ethical excellence to include practical business benefits that directly impact our clients' bottom line. We maintain a strong track record of on-time study delivery, with contingency plans in place to accommodate unexpected scheduling changes or scope modifications without compromising data integrity. Our regulatory affairs team has deep experience preparing study reports that satisfy the requirements of major global health authorities, including the FDA, EMA, PMDA, and NMPA, reducing the risk of data rejection or requests for additional studies during the review process. We offer competitive pricing without sacrificing quality, achieved through operational efficiencies, strategic supply chain management, and continuous process improvement initiatives. Our location in Shanghai provides convenient access for Asian-based clients while our global shipping partnerships ensure reliable sample transport from anywhere in the world. We believe that transparency builds trust, which is why we provide clients with real-time access to study data through our secure online portal and schedule regular teleconference updates throughout the study period. To discuss how Quicking Biotech can support your next project, please visit ourNew Page to contact our team directly.

Quicking Biotech Co., Ltd. stands ready to serve as your trusted partner in generating the high-quality, ethically sound animal testing data that your organization needs to advance its research and development goals. Our comprehensive service portfolio, advanced technological infrastructure, and unwavering commitment to the 3Rs principles make us an ideal choice for companies seeking a contract research organization that prioritizes both scientific excellence and animal welfare. We understand that the decision to conduct animal testing carries significant scientific, ethical, and public relations implications, and we work diligently to ensure that every study we perform meets the highest possible standards of integrity and rigor. By choosing Quicking Biotech, you gain access to a team of dedicated professionals who treat your projects with the same care and attention that they would their own. We invite you to explore our website, review our credentials, and schedule a confidential consultation to discuss how we can support your specific testing requirements. Visit ourHome page to begin your journey toward reliable, ethically generated data that will move your products from concept to market with confidence. Let us help you achieve your research objectives while upholding the values that matter most to your organization and its stakeholders.

Quicking Biotech offers a comprehensive range of animal test studies including acute and chronic toxicity assessments, dermal irritation and sensitization studies, ocular safety evaluations, pharmacokinetic and toxicokinetic profiling, reproductive and developmental toxicity studies, and efficacy trials for pharmaceuticals, vaccines, and medical devices. Our capabilities cover both rodent and non-rodent species, and we design each study protocol to meet specific regulatory requirements and client objectives.

Quicking Biotech operates under a strict ethical framework based on the 3Rs principles of Replacement, Reduction, and Refinement. We maintain AAALAC accreditation, have an active institutional animal care and use committee that reviews all protocols, provide environmental enrichment and social housing for animals, use advanced anesthetic and analgesic protocols, and continuously refine our procedures to minimize any potential pain or distress. Our facilities are designed for animal comfort and our staff receives ongoing training in humane handling techniques.

Yes, Quicking Biotech provides animal testing cosmetics services for companies that require safety data to meet regulatory requirements in markets that still mandate certain animal studies. We apply refined methodologies, including topical anesthetics and reduced exposure protocols, to minimize discomfort, and we work with clients to develop testing strategies that align with their corporate ethical standards while satisfying regulatory demands. We also assist clients in validating in vitro alternative methods where appropriate.

The Draize test is a traditional method for evaluating the eye and skin irritation potential of chemicals and products. Quicking Biotech has modernized this test by incorporating objective measurement tools such as fluorophotometry, confocal microscopy, and digital image analysis to replace subjective visual scoring with quantitative endpoints. We also use topical anesthetics, reduced exposure times, and early humane endpoints to minimize any discomfort while maintaining the scientific validity required for regulatory acceptance.

Yes, Quicking Biotech conducts beagle testing as part of our non-rodent study capabilities, particularly for pharmaceutical safety assessment programs. Our beagle testing protocols include social housing whenever possible, daily environmental enrichment, positive reinforcement training for study procedures, continuous veterinary oversight, and the use of advanced telemetry devices to reduce handling stress. We adhere to all applicable animal welfare regulations and maintain detailed standard operating procedures specifically for canine studies.

Quicking Biotech differentiates itself from other companies that test on animals through our higher ethical standards, advanced technological infrastructure, and transparent client communication. We hold AAALAC accreditation, invest heavily in refinement technologies, provide real-time data access through our online portal, and maintain an open-door policy for ethical audits. Our clients consistently cite our data quality, regulatory expertise, and responsive project management as key advantages over other contract research organizations.

Quicking Biotech complies with OECD Good Laboratory Practice (GLP) principles, FDA GLP regulations (21 CFR Part 58), ICH guidelines for safety studies, and all applicable local and national animal welfare regulations in China. Our facilities are regularly inspected by regulatory authorities and our quality assurance unit conducts internal audits to ensure ongoing compliance. Study reports generated by Quicking Biotech are accepted by regulatory agencies worldwide, including the FDA, EMA, PMDA, and NMPA.

Absolutely. Quicking Biotech employs a team of experienced toxicologists, pharmacologists, and regulatory specialists who work collaboratively with clients to design custom animal test protocols tailored to specific product characteristics, intended indications, and target regulatory markets. We consider factors such as route of administration, dosing regimen, species selection, sample size, endpoints, and statistical power to ensure that the generated data meets both scientific and regulatory requirements efficiently.

Quicking Biotech reduces animal use through several strategies including careful study design with appropriate statistical power calculations, use of telemetry and imaging technologies that allow longitudinal data collection from the same animals, incorporation of multiple endpoints into single studies, and implementation of tiered testing strategies that limit full studies to substances that show concerning signals in preliminary screens. We also actively validate and promote the use of in vitro alternative methods wherever scientifically appropriate.

To start a project with Quicking Biotech, potential clients begin with a confidential consultation to discuss their testing needs, timelines, and budget. Our scientific team then prepares a detailed study proposal including protocol design, species selection, endpoints, and pricing. Once the proposal is accepted, we assign a dedicated project manager who coordinates study initiation, provides regular progress updates, and serves as the client's single point of contact throughout the study. Data is reported through comprehensive final reports with full regulatory documentation.